EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 36 / Numéro 8-9 (Août–Septembre 2020) Med Sci (Paris), 36 8-9 (2020) 753-762 Références
Rétine
Open Access
Numéro
Med Sci (Paris)
Volume 36, Numéro 8-9, Août–Septembre 2020
Rétine
Page(s) 753 - 762
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020130
Publié en ligne 21 août 2020
  1. Bourne RRA, Jonas JB, Bron AM, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol 2018 ; 102 : 575–585. [CrossRef] [PubMed] [Google Scholar]
  2. Omri S, Omri B, Savoldelli M, et al. The outer limiting membrane (OLM) revisited : clinical implications. Clin Ophthalmol Auckl NZ 2010 ; 4 : 183–195. [Google Scholar]
  3. Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema : beyond the surface. Prog Retin Eye Res 2018 ; 63 : 20–68. [CrossRef] [PubMed] [Google Scholar]
  4. Omri S, Behar-Cohen F, Rothschild P-R, et al. PKCζ mediates breakdown of outer blood-retinal barriers in diabetic retinopathy. PLoS One 2013 ; 8 : e81600. [CrossRef] [PubMed] [Google Scholar]
  5. Rothschild PR, Salah S, Berdugo M, et al. ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing : Contribution to diabetic retinopathy. Sci Rep 2017 ; 7 : 8834. [CrossRef] [PubMed] [Google Scholar]
  6. Kowalczuk L, Touchard E, Omri S, et al. Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PLoS One 2011 ; 6 : e17462. [CrossRef] [PubMed] [Google Scholar]
  7. Miyamoto N, de Kozak Y, Jeanny JC, et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown : potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 2007 ; 50 : 461–470. [CrossRef] [PubMed] [Google Scholar]
  8. Omri S, Behar-Cohen F, de Kozak Y, et al. Microglia/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy : role of PKCζ in the Goto Kakizaki rat model. Am J Pathol 2011 ; 179 : 942–953. [CrossRef] [PubMed] [Google Scholar]
  9. Couturier A, Bousquet E, Zhao M, et al. Anti-vascular endothelial growth factor acts on retinal microglia/macrophage activation in a rat model of ocular inflammation. Mol Vis 2014 ; 20 : 908–920. [PubMed] [Google Scholar]
  10. Bousquet E, Zhao M, Thillaye-Goldenberg B, et al. Choroidal mast cells in retinal pathology : a potential target for intervention. Am J Pathol 2015 ; 185 : 2083–2095. [CrossRef] [PubMed] [Google Scholar]
  11. Matet A, Savastano MC, Rispoli M, et al. En face optical coherence tomography of foveal microstructure in full-thickness macular hole : a model to study perifoveal Müller cells. Am J Ophthalmol 2015 ; 159 : 1142–1151 e3. [Google Scholar]
  12. Iliff JJ, Wang M, Liao Y, et al. A Paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 2012; 4 : 147ra111. [CrossRef] [PubMed] [Google Scholar]
  13. Nakada T, Kwee IL, Igarashi H, Suzuki Y. Aquaporin-4 functionality and Virchow-Robin space water dynamics: physiological model for neurovascular coupling and glymphatic flow. Int J Mol Sci 2017 ; 18 : [Google Scholar]
  14. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014 : CD005139. [PubMed] [Google Scholar]
  15. Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular oedema : a network meta-analysis. Cochrane Database Syst Rev 2017; 6 : CD007419. [PubMed] [Google Scholar]
  16. Sangroongruangsri S, Ratanapakorn T, Wu O, et al. Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol 2018 ; 11 : 903–916. [CrossRef] [PubMed] [Google Scholar]
  17. Freund KB, Korobelnik J-F, Devenyi R, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina Phila Pa 2015 ; 35 : 1489–1506. [CrossRef] [Google Scholar]
  18. Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology 2017 ; 124 : 1296–1304. [Google Scholar]
  19. Stewart MW. Extended duration vascular endothelial growth factor iinhibition in the eye: failures, successes, and future possibilities. Pharmaceutics 2018; 10. [Google Scholar]
  20. Moore NA, Morral N, Ciulla TA, Bracha P. Gene therapy for inherited retinal and optic nerve degenerations. Expert Opin Biol Ther 2018 ; 18 : 37–49. [PubMed] [Google Scholar]
  21. Bordet T, Behar-Cohen F. Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives. Drug Discov Today 2019 ; 24 : 1685–1693. [CrossRef] [PubMed] [Google Scholar]
  22. Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol 2014 ; 7 : 167–180. [CrossRef] [PubMed] [Google Scholar]
  23. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999 ; 27 : 536–544. [CrossRef] [PubMed] [Google Scholar]
  24. CATT Research Group, Martin DF, Maguire MG, Ying G, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011 ; 364 : 1897–1908. [Google Scholar]
  25. Xu D, Dávila JP, Rahimi M, et al. Long-term progression of type 1 neovascularization in age-related macular degeneration using optical coherence tomography angiography. Am J Ophthalmol 2018 ; 187 : 10–20. [CrossRef] [PubMed] [Google Scholar]
  26. Fuh G, Wu P, Liang WC, et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006 ; 281 : 6625–6631. [CrossRef] [PubMed] [Google Scholar]
  27. Behar-Cohen F, Dernigoghossian M, Andrieu-Soler C, et al. Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization. Drug Discov Today 2019. https://doi.org/10.1016/j.drudis.2019.05.034. [Google Scholar]
  28. Valamanesh F, Torriglia A, Savoldelli M, et al. Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. Mol Vis 2007 ; 13 : 1746–1757. [PubMed] [Google Scholar]
  29. Valamanesh F, Berdugo M, Sennlaub F, et al. Effects of triamcinolone acetonide on vessels of the posterior segment of the eye. Mol Vis 2009 ; 15 : 2634–2648. [PubMed] [Google Scholar]
  30. Torriglia A, Valamanesh F, Behar-Cohen F. On the retinal toxicity of intraocular glucocorticoids. Biochem Pharmacol 2010 ; 80 : 1878–1886. [CrossRef] [PubMed] [Google Scholar]
  31. Yang Y, Bailey C, Loewenstein A, Massin P. Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina Phila Pa 2015 ; 35 : 2440–2449. [CrossRef] [Google Scholar]
  32. Einmahl S, Savoldelli M, D’Hermies F, et al. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest Ophthalmol Vis Sci 2002 ; 43 : 1533–1539. [PubMed] [Google Scholar]
  33. Daruich A, Matet A, Behar-Cohen F. Sustained-release steroids for the treatment of diabetic macular edema. Curr Diab Rep 2015 ; 15 : 99. [CrossRef] [PubMed] [Google Scholar]
  34. Miyamoto N, Iossifov D, Metge F, Behar-Cohen F. Early effects of intravitreal triamcinolone on macular edema : mechanistic implication. Ophthalmology 2006 ; 113 : 2048–2053. [Google Scholar]
  35. Zhao M, Bousquet E, Valamanesh F, et al. Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina. Invest Ophthalmol Vis Sci 2011 ; 52 : 6340–6347. [CrossRef] [PubMed] [Google Scholar]
  36. Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target : aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J 2010 ; 24 : 3405–3415. [CrossRef] [PubMed] [Google Scholar]
  37. Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: toward New paradigms in clinical pharmacology. Pharmacol Rev 2016 ; 68 : 49–75. [PubMed] [Google Scholar]
  38. Canonica J, Mehanna C, Bonnard B, et al. Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium-choroid complex in rodents. Exp Eye Res 2019 ; 187 : 107747. [CrossRef] [PubMed] [Google Scholar]
  39. Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012 ; 122 : 2672–2679. [CrossRef] [PubMed] [Google Scholar]
  40. Allingham MJ, Tserentsoodol N, Saloupis P, et al. Aldosterone exposure causes increased retinal edema and severe retinopathy following laser-induced retinal vein occlusion in mice. Invest Ophthalmol Vis Sci 2018 ; 59 : 3355–3365. [CrossRef] [PubMed] [Google Scholar]
  41. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 2009 ; 104 : 124–133. [PubMed] [Google Scholar]
  42. Wilkinson-Berka JL, Behar-Cohen F. Angiotensin II and aldosterone: co-conspirators in ocular physiology and disease. Exp Eye Res 2020 : 108005. [CrossRef] [PubMed] [Google Scholar]
  43. Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 2015 ; 48 : 82–118. [CrossRef] [PubMed] [Google Scholar]
  44. Zhao M, Mantel I, Gelize E, et al. Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. Nat Commun 2019 ; 10 : 369. [PubMed] [Google Scholar]
  45. Behar-Cohen F.. Towards an optimized use of ocular corticosteroids: EURETINA award lecture 2017. Ophthalmologica 2018 ; 240 : 111–119. [CrossRef] [PubMed] [Google Scholar]
  46. Behar-Cohen F, Gelizé E, Jonet L, Lassiaz P. Anatomie de la rétine. Med Sci (Paris) 2020; 36 : 594–9. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  47. Thomas JL, Jacob L, Boisserand L. Système lymphatique et cerveau. Med Sci (Paris) 2019 ; 35 : 55–61. [CrossRef] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.